FGFR2 (C491A/V564L)
Sign in to save this workspaceFGFR2 · Variant type: compound · HGVS: p.C491A;p.V564L
Components
p.C491Ap.V564L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 2 | Entrectinib | 97.3% | 2.7% | 93.69 |
| 3 | Selpercatinib | 96.8% | 3.2% | 96.72 |
| 4 | Fedratinib | 95.9% | 4.1% | 96.21 |
| 5 | Defactinib | 95.2% | 4.8% | 92.68 |
| 6 | Sunitinib | 94.8% | 5.2% | 91.73 |
| 7 | Repotrectinib | 92.3% | 7.7% | 84.21 |
| 8 | Erdafitinib | 87.0% | 13.1% | 95.71 |
| 9 | Upadacitinib | 82.3% | 17.7% | 97.98 |
| 10 | Avapritinib | 78.5% | 21.6% | 97.73 |
| 11 | Pacritinib | 76.3% | 23.7% | 88.64 |
| 12 | Pemigatinib | 76.2% | 23.8% | 98.23 |
| 13 | Alpelisib | 72.8% | 27.2% | 97.22 |
| 14 | Gilteritinib | 66.0% | 34.0% | 88.97 |
| 15 | Tivozanib | 64.8% | 35.2% | 92.42 |
| 16 | Tenalisib | 63.8% | 36.2% | 97.98 |
| 17 | Pexidartinib | 57.9% | 42.1% | 99.49 |
| 18 | Infigratinib | 40.2% | 59.8% | 98.24 |
| 19 | Rabusertib | 39.3% | 60.7% | 98.74 |
| 20 | Deucravacitinib | 34.5% | 65.5% | 98.99 |
| 21 | Neratinib | 31.4% | 68.6% | 93.18 |
| 22 | Futibatinib | 27.7% | 72.3% | 98.48 |
| 23 | Darovasertib | 27.5% | 72.5% | 96.99 |
| 24 | Ripretinib | 20.9% | 79.1% | 92.95 |
| 25 | Tepotinib | 17.9% | 82.1% | 99.75 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pralsetinib | 100.0% | 93.2% | +6.8% |
| Entrectinib | 97.3% | 81.5% | +15.7% |
| Selpercatinib | 96.8% | 95.0% | +1.8% |
| Fedratinib | 95.9% | — | — |
| Defactinib | 95.2% | — | — |
| Sunitinib | 94.8% | — | — |
| Repotrectinib | 92.3% | 79.8% | +12.5% |
| Erdafitinib | 87.0% | 99.0% | -12.0% |
| Upadacitinib | 82.3% | — | — |
| Avapritinib | 78.5% | — | — |
| Pacritinib | 76.3% | — | — |
| Pemigatinib | 76.2% | 98.7% | -22.6% |
| Alpelisib | 72.8% | 98.9% | -26.2% |
| Gilteritinib | 66.0% | — | — |
| Tivozanib | 64.8% | — | — |
| Tenalisib | 63.8% | 96.0% | -32.2% |
| Pexidartinib | 57.9% | — | — |
| Infigratinib | 40.2% | 98.8% | -58.6% |
| Rabusertib | 39.3% | — | — |
| Deucravacitinib | 34.5% | 92.5% | -58.0% |
| Neratinib | 31.4% | — | — |
| Futibatinib | 27.7% | 99.3% | -71.6% |
| Darovasertib | 27.5% | — | — |
| Ripretinib | 20.9% | 85.4% | -64.5% |
| Tepotinib | 17.9% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.4ms